相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response
Maria Buti et al.
HEPATOLOGY (2010)
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
Paul Y. Kwo et al.
LANCET (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C
Maribel Rodriguez-Torres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
SCH 503034, a novel hepatitis C virus pro-tease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Discovery of (1R, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor:: A potential therapeutic agent for the treatment of hepatitis C infection
Srikanth Venkatraman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
RT Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
FJ Torriani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
AJ Muir et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study
W Jessner et al.
LANCET (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Epidemiology of hepatitis C: Geographic differences and temporal trends
A Wasley et al.
SEMINARS IN LIVER DISEASE (2000)
分享论文
